1. Pink Sheet
  2. >>Legislation
  3. >>Elections

Warp Speed For All And A Boost For Small Biotechs In Trump’s Second Term, Ex-Official Says

 
• By Sarah Karlin-Smith

Former Trump adviser Tomas Philipson anticipates the FDA will undergo a deregulatory push during President Trump’s second term and emphasize speeding drugs to market.

Training moving fast.
The FDA may aim to speed up agency reviews during Trump's second term. (Shutterstock)

The US Food and Drug Administration will likely experience “a lot of deregulatory pressure” in Trump’s second term and focus on applying the principles of Operation Warp Speed, Trump’s first term COVID-19 vaccine and therapeutic acceleration program, to more product reviews, predicted Tomas Philipson, a White House adviser during Trump’s first term.

Key Takeaways
  • The FDA likely will be pushed to deregulate under Trump, a former White House adviser told the Pink Sheet.

The deregulatory pressure “actually was mounting up before COVID, but then through warp speed got accelerated with COVID, and there was I think, a clear recognition by the White House...

More from Elections

More from Legislation

EU Council Could Adopt Pharma Reform Package Next Week, But Disputes Risk A Year’s Delay

 
• By Eliza Slawther

The Council of the EU wants to adopt its negotiating position on the reform of the general pharmaceutical legislation “sooner, rather than later,” but divergence between member states could push negotiations back another year, a European Commission policy officer said today.

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.